Head to Head Comparison: OS Therapies (OSTX) vs. Its Rivals

OS Therapies (NYSE:OSTX) is one of 450 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare OS Therapies to similar businesses based on the strength of its dividends, earnings, institutional ownership, analyst recommendations, risk, profitability and valuation.

Profitability

This table compares OS Therapies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OS Therapies	N/A	N/A	-569.57%
OS Therapies Competitors	-2,615.58%	-412.72%	-44.45%

Earnings & Valuation

This table compares OS Therapies and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OS Therapies	N/A	-$7.79 million	-1.97
OS Therapies Competitors	$442.11 million	-$69.06 million	-7.59

OS Therapies’ competitors have higher revenue, but lower earnings than OS Therapies. OS Therapies is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

39.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.8% of OS Therapies shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for OS Therapies and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OS Therapies	0	0	3	2	3.40
OS Therapies Competitors	4776	9992	16016	364	2.38

OS Therapies presently has a consensus target price of $18.00, suggesting a potential upside of 965.09%. As a group, “Pharmaceutical preparations” companies have a potential upside of 106.65%. Given OS Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than its competitors.

Summary

OS Therapies beats its competitors on 8 of the 12 factors compared.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.